On March 24, Qingdao Haier Biomedical Co.Ltd(688139) disclosed the 2021 annual report: the company's annual performance continued the high growth trend, realizing a sales revenue of 2.126 billion yuan, a year-on-year increase of 51.63%; The total profit was 961 million yuan, a year-on-year increase of 126.49%; The net profit attributable to the parent company was 845 million yuan, a year-on-year increase of 121.82%. Among them, the revenue of Internet of things solutions business was 668 million yuan, a year-on-year increase of 138.11%, and its proportion in the total revenue increased from 20.01% in 2020 to 31.42%; The proportion of service revenue increased from 3.02% in 2020 to 10.84% in the reporting period, realizing double growth.
The upgrading of the company's Internet of things continued to deepen, focusing on the two digital scenarios of "life science and medical innovation". By continuously increasing the R & D of scientific innovation, deepening the global layout and strengthening the construction of organizational capacity, the company promoted the upgrading of its business model to "product + service", and achieved high-quality development in the complex external environment throughout the year.
Based on the diversified needs of users, the company continues to improve the ability of full scenario and full cycle solutions to meet the "personalized needs of users", and gradually realize the transformation and upgrading of business model from product hardware sales to "product + service" solutions while ensuring the leadership and sustainability of customized solutions. Focusing on the diversification of users, the enrichment of solutions and the globalization of business, we made continuous breakthroughs and innovations, and Qingdao Haier Biomedical Co.Ltd(688139) overall business continued to develop well. Blood safety, drug and reagent safety, sample safety and vaccine safety increased by 266.32%, 49.26%, 21.78% and 102.71% respectively.
In the field of blood safety, scheme replication and innovation go hand in hand. Smart blood city network is replicated and promoted in Hubei, Zhejiang and other places, and iterative innovation of solutions for multiple segmentation scenarios such as hospitals and blood stations. By seizing the opportunity to sink users, the safety scene of drugs and reagents has been continuously deepened in the Chinese and foreign markets, effectively breaking through the user groups in the Americas, Asia Pacific and other regions. For the sample safety scenario, the company strives to expand the diversity of biopharmaceutical users, improve the richness of new scenarios such as biological culture and centrifugal preparation, and quickly replicate and expand under the trend of digital upgrading of the industry. The company promoted the replication of smart vaccine city network and scheme iteration, built more than 4000 smart vaccine vaccination points, innovated the mobile vaccination service mode, and built the great wall of national immunization.
In 2021, relying on the open innovation system of "field → laboratory → market", the company supports business expansion, mode upgrading and long-term development, and provides a continuous endogenous driving force for the construction of digital scene ecology in the two fields of "life science and medical innovation". In 2021, the company's R & D investment reached 236 million yuan, a significant increase of 56.79% over the same period last year. The company continued to produce original technologies. In 2021, it successively broke through the core technologies such as high cooling capacity Stirling ultra-low temperature refrigeration technology, biological culture, centrifugal preparation and so on, so as to realize the continuous enrichment of product categories. The integration of technological innovation such as Internet of things, aiot and automation provides platform support for scenario scheme customization and user delivery capability improvement. Through the open mechanism of "creating win-win and sharing", Qingdao Haier Biomedical Co.Ltd(688139) gathered ecological parties to jointly create aviation temperature control scenarios, and efficiently obtained ctsoa, MDA certificates and IATA codes, laying a solid foundation for the endogenous expansion of business scenarios. During the reporting period, the number of Qingdao Haier Biomedical Co.Ltd(688139) new applications and patents obtained increased by more than 60% year-on-year. The cumulative number of patents obtained reached 539, 33 software copyrights, and 19 national, industrial and group standards and technical specifications were led or participated in.
The company said that in the future, it will comply with the new trend of digital economy development, continue to focus on the two major fields of "life science and medical innovation", adhere to independent innovation and green and low-carbon development, focus on the upgrading of "product + service" business model and the dual industrial layout of "endogenous + extension", build a digital scene ecology, consolidate core competitiveness and comprehensive strength, and promote the high-quality and sustainable development of the company.
